Precision BioSciences, Inc. (NASDAQ:DTIL) Short Interest Up 27.4% in December

Precision BioSciences, Inc. (NASDAQ:DTIL) saw a significant increase in short interest during the month of December. As of December 15th, there was short interest totaling 811,386 shares, an increase of 27.4% from the November 30th total of 636,655 shares. Based on an average daily trading volume, of 187,485 shares, the days-to-cover ratio is presently 4.3 days. Approximately 6.4% of the company’s stock are short sold. Approximately 6.4% of the company’s stock are short sold. Based on an average daily trading volume, of 187,485 shares, the days-to-cover ratio is presently 4.3 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Precision BioSciences in a report on Monday, December 22nd. Two equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Precision BioSciences presently has a consensus rating of “Hold” and a consensus price target of $47.00.

Precision BioSciences Stock Up 2.8%

Precision BioSciences stock opened at $4.42 on Wednesday. The company has a debt-to-equity ratio of 1.35, a quick ratio of 3.45 and a current ratio of 3.45. The business’s 50-day simple moving average is $5.56 and its two-hundred day simple moving average is $5.17. The company has a market cap of $58.60 million, a PE ratio of -0.53 and a beta of 1.11. Precision BioSciences has a fifty-two week low of $3.61 and a fifty-two week high of $8.82.

Precision BioSciences (NASDAQ:DTIL) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($1.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by ($1.53). The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $5.40 million. Precision BioSciences had a negative return on equity of 233.77% and a negative net margin of 11,977.36%.During the same quarter in the previous year, the business earned ($2.25) earnings per share. Equities analysts anticipate that Precision BioSciences will post -1.23 EPS for the current year.

Institutional Trading of Precision BioSciences

Several large investors have recently made changes to their positions in the business. Vanguard Personalized Indexing Management LLC purchased a new position in shares of Precision BioSciences during the third quarter worth $72,000. Virtu Financial LLC acquired a new stake in Precision BioSciences during the 3rd quarter worth about $84,000. GSA Capital Partners LLP purchased a new position in shares of Precision BioSciences during the 3rd quarter valued at about $98,000. Velan Capital Investment Management LP acquired a new position in shares of Precision BioSciences in the 3rd quarter valued at about $110,000. Finally, Citadel Advisors LLC acquired a new position in shares of Precision BioSciences in the 3rd quarter valued at about $122,000. 37.99% of the stock is owned by hedge funds and other institutional investors.

Precision BioSciences Company Profile

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.